Form 8-K · Current Report · Filed 2026-04-02
Roivant Announces New Phase 2b/3 Trial for Brepocitinib in Lichen Planopilaris and Reports Phase 3 Results for Batoclimab in Thyroid Eye Disease
On April 2, 2026, Roivant Sciences Ltd. announced the initiation of a new Phase 2b/3 clinical program for brepocitinib in lichen planopilaris (LPP), a highly morbid inflammatory scalp disorder. The company also reported topline results from Immunovant's two Phase 3 clinical studies evaluating batoclimab as an investigational treatment for adults with active, moderate-to-severe thyroid eye disease (TED). The Phase 3 studies for batoclimab did not meet their primary endpoint, but showed promising results in certain patient subsets. Roivant also provided preliminary unaudited financial information, reporting approximately $4.3 billion in cash, cash equivalents, and marketable securities as of March 31, 2026.
- Filer
- Roivant Sciences Ltd ROIV · NASDAQ
- Filed
- Accession
- 0001140361-26-012885
- CIK
- 0001635088
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$27.84
Next session
+0.1%
Since filing
+24.4%
Latest close
$34.64
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ROIV reporting the same item, with the next session's move:
Exhibits (1)
About Roivant Sciences Ltd
Roivant Sciences Ltd is a biopharmaceutical company focused on developing and commercializing innovative therapies through a unique model that emphasizes rapid and efficient drug delivery. As a platform company, Roivant Sciences incubates subsidiaries known as 'Vants,' each concentrating on a specific therapeutic area. This model allows Roivant to prioritize development of pharmaceuticals in critical areas, including neurology, oncology, immunology, and others. Roivant’s approach facilitates agility in drug development, enabling each Vant to operate semi-autonomously to accelerate research and commercialization efforts. By leveraging technology and data analytics, Roivant enhances drug discovery processes and optimizes clinical trials. In the pharmaceutical industry, Roivant Sciences represents a forward-thinking entity that addresses unmet medical needs by transforming the traditional paradigms of drug development. Its initiatives have substantial implications for healthcare, potentially altering treatment landscapes and improving patient outcomes globally. Founded in 2014 and headquartered in New York City, Roivant is a notable example of innovation-driven pharmaceutical enterprise in the financial market.
Never miss another ROIV filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.